Anzillotti G, Conte P, Bertolino E M, Ferrero A, Di Matteo B, Vacca M, Di Martino M, Altomare D, Magarelli N, Lanza E, Verdonk P, Kon E
IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Eur Rev Med Pharmacol Sci. 2025 Jun;29(6):313-323. doi: 10.26355/eurrev_202506_37273.
OBJECTIVE: Degenerative meniscal lesions consist of an alteration of the meniscal structure, eventually leading to pain and dysfunction. In the absence of mechanical symptoms, meniscectomy should be considered the last resort. Polynucleotides represent a novel treatment option which have shown promising results in different fields, including knee osteoarthritis. Hence, this study aimed to evaluate the safety and efficacy of a cycle of intra- and peri-meniscal polynucleotide injections for the treatment of degenerative meniscus. MATERIALS AND METHODS: This prospective study included 30 patients aged 25-65 with degenerative meniscal tears confirmed by MRI. Eligible patients were treated with three intra- and peri-meniscal injections of polynucleotides, administered with a two-week time interval under ultrasound guidance. The primary outcome was improvement in the overall Knee Injury and Osteoarthritis Outcome Score (KOOS) by at least 10 points from baseline to 12-month follow-up. Secondary outcomes included Visual Analog Scale (VAS) for pain, the International Knee Documentation Committee (IKDC) score, and the Tegner Activity Scale. Safety was assessed through the monitoring of adverse events. RESULTS: Twenty-four patients completed the 12-month follow-up. KOOS scores showed a statistically significant improvement from a mean of 61.99 at baseline to 84.32 at 12 months [95% CI: (79.25, 89.4); p<0.001]. VAS mm scores also decreased significantly, from 62.68 at baseline to 20.63 at 12 months [95% CI, (12.84, 28.41), p<0.001]. Improvements in IKDC and Tegner scores were observed but plateaued after 6 months. No adverse events were reported throughout the entire study period. CONCLUSIONS: A cycle of three intra- and peri-meniscal poly-nucleotides injections is able to provide statistically significant improvements in clinical scores up to 1 year of follow-up in patients affected by symptomatic degenerative meniscus of the knee.
https://www.europeanreview.org/wp/wp-content/uploads/Graphical-abstract-1-2.jpg.
目的:半月板退行性病变包括半月板结构改变,最终导致疼痛和功能障碍。在没有机械症状的情况下,半月板切除术应被视为最后的手段。多核苷酸代表一种新的治疗选择,已在包括膝关节骨关节炎在内的不同领域显示出有前景的结果。因此,本研究旨在评估半月板内和半月板周围多核苷酸注射周期治疗退行性半月板的安全性和有效性。材料和方法:这项前瞻性研究纳入了30名年龄在25 - 65岁之间、经磁共振成像(MRI)确诊为半月板退行性撕裂的患者。符合条件的患者接受了三次半月板内和半月板周围多核苷酸注射,在超声引导下每隔两周进行一次注射。主要结局是从基线到12个月随访时,膝关节损伤和骨关节炎结局评分(KOOS)总体改善至少10分。次要结局包括疼痛视觉模拟评分(VAS)、国际膝关节文献委员会(IKDC)评分和泰格纳活动量表。通过监测不良事件评估安全性。结果:24名患者完成了12个月的随访。KOOS评分显示出从基线时的平均61.99显著提高到12个月时 的84.32 [95%置信区间:(79.25,89.4);p<0.001]。VAS毫米评分也显著降低,从基线时的62.68降至12个月时 的20.63 [95%置信区间,(12.84,28.41),p<0.001]。观察到IKDC和泰格纳评分有所改善,但在6个月后趋于平稳。在整个研究期间未报告不良事件。结论:对于膝关节有症状的退行性半月板患者,三次半月板内和半月板周围多核苷酸注射周期能够在长达1年的随访中使临床评分有统计学意义的改善。
https://www.europeanreview.org/wp/wp-content/uploads/Graphical-abstract-1-2.jpg。